331 related articles for article (PubMed ID: 16503809)
1. Individualization of mycophenolate mofetil dose in renal transplant recipients.
van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T
Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809
[TBL] [Abstract][Full Text] [Related]
2. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection.
Nicholls AJ
Clin Biochem; 1998 Jul; 31(5):329-33. PubMed ID: 9721430
[No Abstract] [Full Text] [Related]
3. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
Fulton B; Markham A
Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.
Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA
Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
van Hest RM; van Gelder T; Vulto AG; Mathot RA
Clin Pharmacokinet; 2005; 44(10):1083-96. PubMed ID: 16176120
[TBL] [Abstract][Full Text] [Related]
7. [Mycophenolate mofetil in renal transplantation].
Uchida K
Nihon Rinsho; 2005 May; 63 Suppl 5():684-91. PubMed ID: 15954430
[No Abstract] [Full Text] [Related]
8. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring?
Cox VC; Ensom MH
Ther Drug Monit; 2003 Apr; 25(2):137-57. PubMed ID: 12657908
[TBL] [Abstract][Full Text] [Related]
9. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.
van Hest RM; Mathot RA; Pescovitz MD; Gordon R; Mamelok RD; van Gelder T
J Am Soc Nephrol; 2006 Mar; 17(3):871-80. PubMed ID: 16452491
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil: a unique immunosuppressive agent.
Hood KA; Zarembski DG
Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
van Gelder T; Le Meur Y; Shaw LM; Oellerich M; DeNofrio D; Holt C; Holt DW; Kaplan B; Kuypers D; Meiser B; Toenshoff B; Mamelok RD
Ther Drug Monit; 2006 Apr; 28(2):145-54. PubMed ID: 16628123
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant mycophenolate mofetil pharmacokinetics in Mexican children.
Villa M; González R; García-Roca P; Hernández AM; Ortiz L; Castañeda-Hernández G; Medeiros M
Proc West Pharmacol Soc; 2011; 54():66-8. PubMed ID: 22423584
[TBL] [Abstract][Full Text] [Related]
13. [Immunosuppressive drug monitoring of cyclosporine, tacrolimus, and mycophenolate mofetil in renal transplantation].
Uchida K
Nihon Jinzo Gakkai Shi; 2005; 47(4):423-9. PubMed ID: 15971884
[No Abstract] [Full Text] [Related]
14. Mycophenolate mofetil in cardiac transplantation.
Kobashigawa JA
Curr Opin Cardiol; 1998 Mar; 13(2):117-21. PubMed ID: 9593551
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
[TBL] [Abstract][Full Text] [Related]
16. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
Su VCh; Greanya ED; Ensom MH
Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients.
Cattaneo D; Cortinovis M; Baldelli S; Bitto A; Gotti E; Remuzzi G; Perico N
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1147-55. PubMed ID: 17928466
[TBL] [Abstract][Full Text] [Related]
18. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy.
Schwarz C; Regele H; Huttary N; Wahrmann M; Exner M; Nagy-Bojarsky K; Kletzmayr J; Hörl WH; Böhmig GA
Wien Klin Wochenschr; 2006 Jul; 118(13-14):397-404. PubMed ID: 16865644
[TBL] [Abstract][Full Text] [Related]
19. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center.
Deierhoi MH; Kauffman RS; Hudson SL; Barber WH; Curtis JJ; Julian BA; Gaston RS; Laskow DA; Diethelm AG
Ann Surg; 1993 May; 217(5):476-82; discussion 482-4. PubMed ID: 8489310
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
